Cargando…
Comprehensive (18)F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study
PURPOSE: To develop a comprehensive PET radiomics model to predict the pathological response after neoadjuvant toripalimab with chemotherapy in resectable stage III non-small-cell lung cancer (NSCLC) patients. METHODS: Stage III NSCLC patients who received three cycles of neoadjuvant toripalimab wit...
Autores principales: | Cui, Yingpu, Lin, Yaobin, Zhao, Zerui, Long, Hao, Zheng, Lie, Lin, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713843/ https://www.ncbi.nlm.nih.gov/pubmed/36466929 http://dx.doi.org/10.3389/fimmu.2022.994917 |
Ejemplares similares
-
(18)F‐FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma
por: Wang, Shuohua, et al.
Publicado: (2023) -
Delta-radiomics based on CT predicts pathologic complete response in ESCC treated with neoadjuvant immunochemotherapy and surgery
por: Li, Kaiyuan, et al.
Publicado: (2023) -
Multiparametric (18)F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Umutlu, Lale, et al.
Publicado: (2022) -
External validation of (18)F-FDG PET-based radiomic models on identification of residual oesophageal cancer after neoadjuvant chemoradiotherapy
por: Valkema, Maria J., et al.
Publicado: (2023) -
Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)